Evogene Stock Today
| EVGN Stock | USD 1.42 0.04 2.90% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Evogene is selling at 1.42 as of the 25th of February 2025; that is 2.90 percent increase since the beginning of the trading day. The stock's open price was 1.38. Evogene has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 25th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of March 2008 | Category Healthcare | Classification Health Care |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. Evogene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.51 M outstanding shares of which 13.14 K shares are currently shorted by private and institutional investors with about 0.36 trading days to cover. More on Evogene
Moving against Evogene Stock
| 0.36 | RNAC | Cartesian Therapeutics Earnings Call Next Week | PairCorr |
Evogene Stock Highlights
| CEO President | Ofer CPA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Chemicals (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Chemicals, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEvogene can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Evogene's financial leverage. It provides some insight into what part of Evogene's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evogene (EVGN) is traded on NASDAQ Exchange in USA. It is located in 13 Gad Feinstein Street, Rehovot, Israel, 7638517 and employs 142 people. Evogene is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.56 M. Evogene conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.51 M outstanding shares of which 13.14 K shares are currently shorted by private and institutional investors with about 0.36 trading days to cover.
Evogene currently holds about 35.25 M in cash with (21.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86.
Check Evogene Probability Of Bankruptcy
Ownership AllocationRoughly 90.77 percent of Evogene outstanding shares are held by general public with 1.56 (percent) owned by insiders and only 7.67 % by other corporate entities.
Check Evogene Ownership Details
Evogene Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Royal Bank Of Canada | 2024-12-31 | 42.0 | |
| Synergy Financial Management, Llc | 2024-12-31 | 20.0 | |
| Bank Of America Corp | 2024-12-31 | 6.0 | |
| Silverarc Capital Management, Llc | 2024-12-31 | 0.0 | |
| Tower Research Capital Llc | 2024-12-31 | 0.0 | |
| Renaissance Investment Group, Llc | 2024-12-31 | 0.0 | |
| Pnc Financial Services Group Inc | 2024-12-31 | 0.0 | |
| Armistice Capital, Llc | 2024-12-31 | 298.3 K | |
| Ubs Group Ag | 2024-12-31 | 22 K | |
| Jane Street Group Llc | 2024-12-31 | 21.3 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 14.6 K |
Evogene Historical Income Statement
Evogene Stock Against Markets
Evogene Corporate Management
| Rachel Gerber | Head Relations | Profile | |
| Russ Putland | Vice Ltd | Profile | |
| Amit res | Chief Ltd | Profile | |
| Dan Gelvan | Chief Ltd | Profile | |
| Dotan Borenstein | Chief Ltd | Profile | |
| Yaron Eldad | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.46) | Revenue Per Share | Quarterly Revenue Growth (0.52) | Return On Assets | Return On Equity |
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.